StageZero Life Sciences (TSX:SZLS) YoY EBITDA Growth : -366.67% (As of Sep. 2023)

View and export this data going back to 2001. Start your Free Trial

What is StageZero Life Sciences YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. StageZero Life Sciences's YoY EBITDA Growth for the quarter that ended in Sep. 2023 was -366.67%.

StageZero Life Sciences's EBITDA per Share for the three months ended in Sep. 2023 was C$-0.01.

StageZero Life Sciences YoY EBITDA Growth Historical Data

The historical data trend for StageZero Life Sciences's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences YoY EBITDA Growth Chart

StageZero Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

YoY EBITDA Growth

Get a 7-Day Free Trial

14.35

50.25

-84.69

32.04

-19.51

StageZero Life Sciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
YoY EBITDA Growth	Get a 7-Day Free Trial															109.68	-337.93	-266.67	75.00	-366.67

StageZero Life Sciences YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

StageZero Life Sciences's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

	YoY EBITDA Growth (A: Dec. 2022 )
=	(EBITDA per Share (A: Dec. 2022 )	-	EBITDA per Share (A: Dec. 2021 ))	/	\| EBITDA per Share (A: Dec. 2021 ) \|
=	(-0.147	-	-0.123)	/	\| -0.123 \|
=	-19.51 %

StageZero Life Sciences's YoY EBITDA Growth for the quarter that ended in Sep. 2023 is calculated as:

	YoY EBITDA Growth (Q: Sep. 2023 )
=	(EBITDA per Share (Q: Sep. 2023 )	-	EBITDA per Share (Q: Sep. 2022 ))	/	\| EBITDA per Share (Q: Sep. 2022 )) \|
=	(-0.008	-	0.003)	/	\| 0.003 \|
=	-366.67 %

StageZero Life Sciences YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

StageZero Life Sciences (TSX:SZLS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (TSX:SZLS) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

SZLSF:USA 61N1:Germany

Address

70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2

Website

https://www.stagezerolifesciences.com

StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.

StageZero Life Sciences (TSX:SZLS) Headlines

No Headlines